Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.
暂无分享，去创建一个
A. Hauschild | K. Flaherty | P. Ascierto | R. Dummer | J. Sosman | A. Ribas | A. Testori | C. Garbe | P. Chapman | G. McArthur | J. Haanen | D. Hogg | P. Lorigan | K. Nolop | B. Nelson | J. Hou | C. Robert | R. Lee | J. Larkin | S. O'Day